NH SPAC 2 (206640) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NH SPAC 2 (206640) has a cash flow conversion efficiency ratio of 0.043x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩10.46 Billion ≈ $7.09 Million USD) by net assets (₩244.18 Billion ≈ $165.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 206640 net asset quality index to measure how much of total assets are equity-financed.
NH SPAC 2 - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how NH SPAC 2's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is NH SPAC 2's earnings quality to evaluate the quality of earnings relative to operating cash generation.
NH SPAC 2 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NH SPAC 2 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sparebank 1 Nordvest
OL:SNOR
|
-0.029x |
|
Bonei Hatichon Civil Engineering and Infrastructures Ltd
TA:BOTI
|
-0.557x |
|
Sea Sonic Electronics Co Ltd
TWO:6203
|
0.076x |
|
Formosa Optical Technology Co Ltd
TWO:5312
|
0.085x |
|
Premia S.A.
AT:PREMIA
|
0.007x |
|
Power Nickel Inc
V:PNPN
|
-0.844x |
|
CTT Systems AB
ST:CTT
|
-0.034x |
|
Omiris AG
F:HBD1
|
N/A |
Annual Cash Flow Conversion Efficiency for NH SPAC 2 (2015–2025)
The table below shows the annual cash flow conversion efficiency of NH SPAC 2 from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see how much is NH SPAC 2 worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩244.18 Billion ≈ $165.48 Million |
₩22.08 Billion ≈ $14.96 Million |
0.090x | -18.92% |
| 2024-12-31 | ₩223.05 Billion ≈ $151.16 Million |
₩24.88 Billion ≈ $16.86 Million |
0.112x | -35.80% |
| 2023-12-31 | ₩197.42 Billion ≈ $133.79 Million |
₩34.30 Billion ≈ $23.24 Million |
0.174x | +23.18% |
| 2022-12-31 | ₩163.56 Billion ≈ $110.84 Million |
₩23.07 Billion ≈ $15.63 Million |
0.141x | -57.32% |
| 2021-12-31 | ₩151.09 Billion ≈ $102.39 Million |
₩49.93 Billion ≈ $33.83 Million |
0.330x | -11.28% |
| 2020-12-31 | ₩119.86 Billion ≈ $81.23 Million |
₩44.64 Billion ≈ $30.25 Million |
0.372x | +58.88% |
| 2019-12-31 | ₩73.55 Billion ≈ $49.84 Million |
₩17.24 Billion ≈ $11.68 Million |
0.234x | +188.18% |
| 2018-12-31 | ₩65.33 Billion ≈ $44.27 Million |
₩5.31 Billion ≈ $3.60 Million |
0.081x | +522.67% |
| 2017-12-31 | ₩67.87 Billion ≈ $46.00 Million |
₩886.74 Million ≈ $600.93K |
0.013x | -91.67% |
| 2016-12-31 | ₩75.17 Billion ≈ $50.94 Million |
₩11.79 Billion ≈ $7.99 Million |
0.157x | -3.10% |
| 2015-12-31 | ₩59.50 Billion ≈ $40.32 Million |
₩9.63 Billion ≈ $6.53 Million |
0.162x | -- |
About NH SPAC 2
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more